QIAGEN Reports Q1 2026 Results
QIAGEN N.V. announced its full results for Q1 2026, revealing strong profitability with adjusted diluted EPS meeting expectations. However, sales trends were mixed due to decreased QuantiFERON sales and cautious demand from U.S. Life Sciences customers, despite solid growth in other areas of the portfolio.
VENLO, Netherlands–(BUSINESS WIRE)—- $QGEN #QIAGEN–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today reports full results for the first quarter of 2026 in line with the preliminary announcement, showing QIAGEN continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio. As announced April 27, net s